Reversed-Phase LC Isolates Potent Insecticidal Protein From Tarantula
A novel orally active insecticidal peptide (OAIP-1) has been isolated from the venom of one of Australia's largest spiders, the Australian tarantula (Selenotypus plumipes) using reversed-phase liquid chromatography (reversed-phase LC) coupled with mass spectrometry (MS). The study was recently published in the journal PLOS ONE.1
A novel orally active insecticidal peptide (OAIP-1) has been isolated from the venom of one of Australia’s largest spiders, the Australian tarantula (Selenotypus plumipes) using reversed-phase liquid chromatography (reversed-phase LC) coupled with mass spectrometry (MS). The study was recently published in the journal PLOS ONE.1
Insect pests are an affliction on the agricultural industry, reducing world crops by 10–14% annually. Margaret Hardy of the University of Queensland, Australia, told The Column that there is a need to develop new environmentally friendly insecticides, driven by the increasing levels of insecticide resistance. Recently developed insecticides are highly selective and specific, often targeting a small number of molecular targets. Evolution of these targets over time eventually renders the insecticide ineffective. Hardy added that “green” insecticides need to be included in integrated pest management (IPM) programmes to limit their environmental impact.
The tarantula injects venom into its prey using a needle-like fang, and so it has been assumed that it is not a source of orally‑active peptides, which are effective when ingested by insects. The group has previous experience with spider venom peptides with insecticidal activity, but this was the first time they had performed this method. “The manuscript describes the first instance of a directed-discovery programme that successfully isolated a novel, orally-active insecticide,” said Hardy.
Venom was collected from Australian tarantulas and subsequently lypophilized. Reversed-phase LC coupled with MS was performed to isolate and analyse toxins within the venom. Around 50 peaks resulted, with one elution faction displaying oral insecticidal action against tested specimens (including mealworms and termites). A 34-residue orally active insecticidal peptide (OAIP‑1) was identified. The structure of the peptide, was determined by nuclear magnetic resonance (NMR) spectroscopy and indicated high thermal and chemical stability. According to the paper, this suggests the potential to produce the peptide via a synthetic pathway.
“Our results are significant because it describes the discovery of the most potent insecticidal peptide published to date; the insecticide shows synergism with another, currently used conventional insecticide; and, because the peptide could be used as part of an IPM programme,“ said Hardy.Hardy added that the group has already filed patents on the technology used and that future work will focus on determining the safety of the peptide for non-targeted species. - B.D.
Reference
M.C. Hardy et al., PLoS ONE8(9), e73136 (2013).
This story originally appeared in The Column. Click here to view that issue.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.
